Cargando…

Using machine learning to predict individual patient toxicities from cancer treatments

PURPOSE: Machine learning (ML) is a powerful tool for interrogating datasets and learning relationships between multiple variables. We utilized a ML model to identify those early breast cancer (EBC) patients at highest risk of developing severe vasomotor symptoms (VMS). METHODS: A gradient boosted d...

Descripción completa

Detalles Bibliográficos
Autores principales: Cole, Katherine Marie, Clemons, Mark, McGee, Sharon, Alzahrani, Mashari, Larocque, Gail, MacDonald, Fiona, Liu, Michelle, Pond, Gregory R., Mosquera, Lucy, Vandermeer, Lisa, Hutton, Brian, Piper, Ardelle, Fernandes, Ricardo, Emam, Khaled El
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9385785/
https://www.ncbi.nlm.nih.gov/pubmed/35614153
http://dx.doi.org/10.1007/s00520-022-07156-6
_version_ 1784769664860028928
author Cole, Katherine Marie
Clemons, Mark
McGee, Sharon
Alzahrani, Mashari
Larocque, Gail
MacDonald, Fiona
Liu, Michelle
Pond, Gregory R.
Mosquera, Lucy
Vandermeer, Lisa
Hutton, Brian
Piper, Ardelle
Fernandes, Ricardo
Emam, Khaled El
author_facet Cole, Katherine Marie
Clemons, Mark
McGee, Sharon
Alzahrani, Mashari
Larocque, Gail
MacDonald, Fiona
Liu, Michelle
Pond, Gregory R.
Mosquera, Lucy
Vandermeer, Lisa
Hutton, Brian
Piper, Ardelle
Fernandes, Ricardo
Emam, Khaled El
author_sort Cole, Katherine Marie
collection PubMed
description PURPOSE: Machine learning (ML) is a powerful tool for interrogating datasets and learning relationships between multiple variables. We utilized a ML model to identify those early breast cancer (EBC) patients at highest risk of developing severe vasomotor symptoms (VMS). METHODS: A gradient boosted decision model utilizing cross-sectional survey data from 360 EBC patients was created. Seventeen patient- and treatment-specific variables were considered in the model. The outcome variable was based on the Hot Flush Night Sweats (HFNS) Problem Rating Score, and individual scores were dichotomized around the median to indicate individuals with high and low problem scores. Model accuracy was assessed using the area under the receiver operating curve, and conditional partial dependence plots were constructed to illustrate relationships between variables and the outcome of interest. RESULTS: The model area under the ROC curve was 0.731 (SD 0.074). The most important variables in the model were as follows: the number of hot flashes per week, age, the prescription, or use of drug interventions to manage VMS, whether patients were asked about VMS in routine follow-up visits, and the presence or absence of changes to breast cancer treatments due to VMS. A threshold of 17 hot flashes per week was identified as being more predictive of severe VMS. Patients between the ages of 49 and 63 were more likely to report severe symptoms. CONCLUSION: Machine learning is a unique tool for predicting severe VMS. The use of ML to assess other treatment-related toxicities and their management requires further study. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00520-022-07156-6.
format Online
Article
Text
id pubmed-9385785
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-93857852022-08-19 Using machine learning to predict individual patient toxicities from cancer treatments Cole, Katherine Marie Clemons, Mark McGee, Sharon Alzahrani, Mashari Larocque, Gail MacDonald, Fiona Liu, Michelle Pond, Gregory R. Mosquera, Lucy Vandermeer, Lisa Hutton, Brian Piper, Ardelle Fernandes, Ricardo Emam, Khaled El Support Care Cancer Original Article PURPOSE: Machine learning (ML) is a powerful tool for interrogating datasets and learning relationships between multiple variables. We utilized a ML model to identify those early breast cancer (EBC) patients at highest risk of developing severe vasomotor symptoms (VMS). METHODS: A gradient boosted decision model utilizing cross-sectional survey data from 360 EBC patients was created. Seventeen patient- and treatment-specific variables were considered in the model. The outcome variable was based on the Hot Flush Night Sweats (HFNS) Problem Rating Score, and individual scores were dichotomized around the median to indicate individuals with high and low problem scores. Model accuracy was assessed using the area under the receiver operating curve, and conditional partial dependence plots were constructed to illustrate relationships between variables and the outcome of interest. RESULTS: The model area under the ROC curve was 0.731 (SD 0.074). The most important variables in the model were as follows: the number of hot flashes per week, age, the prescription, or use of drug interventions to manage VMS, whether patients were asked about VMS in routine follow-up visits, and the presence or absence of changes to breast cancer treatments due to VMS. A threshold of 17 hot flashes per week was identified as being more predictive of severe VMS. Patients between the ages of 49 and 63 were more likely to report severe symptoms. CONCLUSION: Machine learning is a unique tool for predicting severe VMS. The use of ML to assess other treatment-related toxicities and their management requires further study. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00520-022-07156-6. Springer Berlin Heidelberg 2022-05-25 2022 /pmc/articles/PMC9385785/ /pubmed/35614153 http://dx.doi.org/10.1007/s00520-022-07156-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Cole, Katherine Marie
Clemons, Mark
McGee, Sharon
Alzahrani, Mashari
Larocque, Gail
MacDonald, Fiona
Liu, Michelle
Pond, Gregory R.
Mosquera, Lucy
Vandermeer, Lisa
Hutton, Brian
Piper, Ardelle
Fernandes, Ricardo
Emam, Khaled El
Using machine learning to predict individual patient toxicities from cancer treatments
title Using machine learning to predict individual patient toxicities from cancer treatments
title_full Using machine learning to predict individual patient toxicities from cancer treatments
title_fullStr Using machine learning to predict individual patient toxicities from cancer treatments
title_full_unstemmed Using machine learning to predict individual patient toxicities from cancer treatments
title_short Using machine learning to predict individual patient toxicities from cancer treatments
title_sort using machine learning to predict individual patient toxicities from cancer treatments
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9385785/
https://www.ncbi.nlm.nih.gov/pubmed/35614153
http://dx.doi.org/10.1007/s00520-022-07156-6
work_keys_str_mv AT colekatherinemarie usingmachinelearningtopredictindividualpatienttoxicitiesfromcancertreatments
AT clemonsmark usingmachinelearningtopredictindividualpatienttoxicitiesfromcancertreatments
AT mcgeesharon usingmachinelearningtopredictindividualpatienttoxicitiesfromcancertreatments
AT alzahranimashari usingmachinelearningtopredictindividualpatienttoxicitiesfromcancertreatments
AT larocquegail usingmachinelearningtopredictindividualpatienttoxicitiesfromcancertreatments
AT macdonaldfiona usingmachinelearningtopredictindividualpatienttoxicitiesfromcancertreatments
AT liumichelle usingmachinelearningtopredictindividualpatienttoxicitiesfromcancertreatments
AT pondgregoryr usingmachinelearningtopredictindividualpatienttoxicitiesfromcancertreatments
AT mosqueralucy usingmachinelearningtopredictindividualpatienttoxicitiesfromcancertreatments
AT vandermeerlisa usingmachinelearningtopredictindividualpatienttoxicitiesfromcancertreatments
AT huttonbrian usingmachinelearningtopredictindividualpatienttoxicitiesfromcancertreatments
AT piperardelle usingmachinelearningtopredictindividualpatienttoxicitiesfromcancertreatments
AT fernandesricardo usingmachinelearningtopredictindividualpatienttoxicitiesfromcancertreatments
AT emamkhaledel usingmachinelearningtopredictindividualpatienttoxicitiesfromcancertreatments